Brief: Belite Bio Receives Approval Of LBS-008 Phase 3 Clinical Trial In China
16/09/2022 13:11
Sept 16 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO RECEIVES APPROVAL OF LBS-008 PHASE 3 CLINICAL
TRIAL
IN CHINA
* BELITE BIO - LBS-008 BEEN GRANTED FAST TRACK DESIGNATION &
RARE
PEDIATRIC DISEASE DESIGNATION IN US & ORPHAN DRUG DESIGNATION IN
US & EUROPE FOR STGD1
Source text for Eikon: ID:nGNX5T02gv
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses